↓ Skip to main content
What is this page? Embed badge

Cardiovascular Safety in Drug Development and Therapeutic Use

Overview of attention for book
Cover of 'Cardiovascular Safety in Drug Development and Therapeutic Use'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 The Central Role of Cardiovascular Safety in Drug Development and Therapeutic Use
  3. Altmetric Badge
    Chapter 2 Drug Structures and the Biological Basis of Drug Responses
  4. Altmetric Badge
    Chapter 3 Cardiovascular Structure, Function, and Pathophysiology
  5. Altmetric Badge
    Chapter 4 Analyzing and Reporting Efficacy Data
  6. Altmetric Badge
    Chapter 5 Analyzing and Reporting Safety Data
  7. Altmetric Badge
    Chapter 6 Meta-analysis, Group Sequential Study Designs, Centralized Endpoint Adjudication, and Composite Endpoints
  8. Altmetric Badge
    Chapter 7 The Proarrhythmic Cardiac Safety Regulatory Landscape Circa 2005–2015: Drug-Induced hERG Channel Block and the Thorough QT/QTc Study
  9. Altmetric Badge
    Chapter 8 QTc Exposure–Response Modeling as a Primary Methodology for Proarrhythmic Cardiac Safety Assessments
  10. Altmetric Badge
    Chapter 9 The Comprehensive In Vitro Proarrhythmia Assay Initiative
  11. Altmetric Badge
    Chapter 10 Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology
  12. Altmetric Badge
    Chapter 11 Blood Pressure Responses to Noncardiovascular Drugs in Development and Therapeutic Use
  13. Altmetric Badge
    Chapter 12 The Genesis of Cardiovascular Safety Regulatory Landscapes for New Antidiabetic Drugs for Type 2 Diabetes
  14. Altmetric Badge
    Chapter 13 Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously
  15. Altmetric Badge
    Chapter 14 Postmarketing Cardiovascular Safety Considerations
  16. Altmetric Badge
    Chapter 15 A Safety Perspective on Additional Aspects of Drug Development and Therapeutic Use
Attention for Chapter 13: Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
1 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously
Chapter number 13
Book title
Cardiovascular Safety in Drug Development and Therapeutic Use
Published by
Springer International Publishing, July 2016
DOI 10.1007/978-3-319-40347-2_13
Book ISBNs
978-3-31-940345-8, 978-3-31-940347-2
Authors

J. Rick Turner, Dilip R. Karnad, Snehal Kothari

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 1 100%

Demographic breakdown

Readers by professional status Count As %
Professor > Associate Professor 1 100%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 100%

This page is provided by Altmetric.